Incyte Corp

INCY is in a clear Stage 2 advancing regime with strong medium- and long-term uptrends. Price recently pulled back into the rising 9 and 20 EMAs and held, signaling acceptance at dynamic support and presenting a favorable entry point. Although extreme overbought conditions warrant caution, the shallow retracement and supporting volume justify a Buy Now on this pullback. Low transition risk and healthy EMA alignment underpin the bullish tilt.

• ↑Opsalura CHMP approval paves EU launch addressing moderate atopic dermatitis.
• ↑Q1 revenue reached $1.1B (+20% YoY); 2026 sales guidance +10–13%.
• ↓R&D spending climbed to $611M (+31% YoY), straining operating margins.